VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ORIC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksORICInstitutional Holders

ORIC logoORIC Pharmaceuticals, Inc. (ORIC) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership increased this quarter (+4.37 pp), with a relatively well-distributed shareholder base.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
119.7%$1.3B total value · ▲ +4.37 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
60 / 100Bullish
Institutions & Flow177 holders-3 net flow (+26 / -29)

AI Insights & Key Takeaways

  • Negative Institutional Flow (-3)
  • Viking Global Investors Lp and Citadel Advisors Llc maintain significant positions
  • Top 10 holders control 44.1% of institutional value
  • No Insider Signal

Top Institutional Holders of ORIC

Ranked by reported Q2 2026 13F market value

Top 10 Holders
44.1%
Top 25 Holders
74.1%

Share of total reported institutional value in ORIC held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1Nextech Invest Ltd.7.2M$77.6M0.0%6.919%3.68%
2BlackRock, Inc.6.8M$73.9M+14.0%6.592%0.00%
3EcoR1 Capital, LLC6.7M$72.9M0.0%6.499%3.54%

Quarterly Institutional Activity

Filings activity in ORIC during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers26Added To57Trimmed91Exited29
  • Nextech Invest Ltd.$77.6M
  • BlackRock, Inc.$73.9M
  • EcoR1 Capital, LLC

ORIC Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 20261771.1%119.73%+4.37 pp$1.27B12%
Q1 2026179+9.1%115.36%6.09 pp$1.43B+52%
Q4 2025164+13%121.45%+11.86 pp$946M24%
Q3 2025145+4.3%109.59%+1.30 pp$1.24B+36%
Q2 20251391.4%108.29%2.31 pp$915M+113%
Q1 2025141

How ORIC Compares to Peers

Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
DMRADamora Therapeutics, Inc.$1.46B200.0%99+33
FTHFaeth Therapeutics, Inc.$568M54.5%45+16
LONALeonaBio, Inc.$17M184.4%45+4
KYNBKyntra Bio, Inc.$15M26.9%29-4
CNSYCerenome, Inc.$5M4.8%24-5

ORIC — Frequently Asked Questions

Quick answers to the most common questions about buying ORIC stock.

What percentage of ORIC is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of ORIC Pharmaceuticals, Inc. stands at 119.7%, held across 177 reporting institutions.

Who is the largest institutional holder of ORIC?

Nextech Invest Ltd. is the largest reported institutional holder of ORIC, with approximately 7,162,637 shares worth $0.08B as of Q2 2026.

Is ORIC a hedge fund favorite?

Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of ORIC, including VIKING GLOBAL INVESTORS LP, CITADEL ADVISORS LLC.

What is ORIC's Smart Money Score?

Our composite Smart Money Score for ORIC is 60 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought ORIC this quarter?
4
VIKING GLOBAL INVESTORS LP
5.1M
$55.5M
-12.0%
4.953%
0.16%
5STATE STREET CORP4.9M$53.0M+32.2%4.728%0.00%
6SR ONE CAPITAL MANAGEMENT, LP4.6M$50.0M+2.2%4.459%4.81%
7Venrock Adviser, LLC4.3M$46.8M0.0%4.173%1.42%
8NEA Management Company, LLC4.1M$44.6M0.0%3.979%2.81%
9VANGUARD CAPITAL MANAGEMENT LLC4.0M$42.8M+7.2%3.817%0.00%
10AIHC Capital Management Ltd3.8M$41.5M+55.7%3.698%39.77%
11ALKEON CAPITAL MANAGEMENT LLC3.7M$40.5M-17.0%3.612%0.05%
12Column Group LLC3.5M$38.3M0.0%3.421%43.53%
13Siren, L.L.C.3.0M$32.5M0.0%2.896%0.66%
14FMR LLC2.6M$28.5M+8.3%2.546%0.00%
15CITADEL ADVISORS LLC2.6M$28.4M+7.8%2.532%0.00%
16GOLDMAN SACHS GROUP INC2.5M$26.6M+66.1%2.369%0.00%
17GEODE CAPITAL MANAGEMENT, LLC2.1M$22.6M+13.7%2.019%0.00%
18First Turn Management, LLC2.0M$21.8M0.0%1.949%2.34%
19ORBIMED ADVISORS LLC2.0M$21.8M-25.2%1.946%0.40%
20Integral Health Asset Management, LLC1.9M$20.6M+35.7%1.835%0.81%
21MPM BioImpact LLC1.9M$20.4M+4.3%1.818%1.24%
22Vivo Capital, LLC1.8M$20.0M0.0%1.786%1.83%
23DIMENSIONAL FUND ADVISORS LP1.8M$19.5M+22.4%1.740%0.00%
24FRANKLIN TEMPLETON INC1.8M$19.5M+23.7%1.736%0.00%
25MORGAN STANLEY1.8M$19.4M+6.6%1.733%0.00%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ORIC — a direct measure of their conviction.

$72.9M
  • VIKING GLOBAL INVESTORS LP$55.5M
  • SR ONE CAPITAL MANAGEMENT, LP$50.0M
  • Venrock Adviser, LLC$46.8M
  • NEA Management Company, LLC$44.6M
  • VANGUARD CAPITAL MANAGEMENT LLC$42.8M
  • ALKEON CAPITAL MANAGEMENT LLC$40.5M
  • Column Group LLC$38.3M
  • Siren, L.L.C.$32.5M
  • FMR LLC$28.5M
  • +9.3%
    110.60%
    +6.05 pp
    $430M
    27%
    Q4 2024129+6.6%104.55%+5.68 pp$587M16%
    Q3 2024121—98.87%—$700M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    26 institutions opened new positions in ORIC during Q2 2026, while 29 fully exited. 57 added to existing positions and 91 trimmed.

    How is institutional ownership of ORIC changing?

    ORIC institutional ownership rose by 4.37 percentage points quarter-over-quarter, with a net change of -2 holders.

    How concentrated is ORIC ownership among the top holders?

    The top 10 institutions account for 44.1% of all reported 13F value in ORIC, and the top 25 account for 74.1%.

    How does ORIC compare to Oncology Biotech on institutional ownership?

    Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.

    Where does this ORIC institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    ORICORIC Pharmaceuticals, Inc.
    $7.65$792M
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership